Abstracts tagged "quality of life"

Abstract Number: 0683 • ACR Convergence 2023
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Duvuru Geetha¹, Frank Cortazar², Annette Bruchfeld³, alexandre Karras⁴, Peter Merkel⁵ and David Jayne⁶, ¹Johns Hopkins University, Baltimore, MD, ²New York Nephrology, Watervliet, NY, ³Karolinska Institutet, Stockholm, Sweden, ⁴HEGP - APHP, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…
Abstract Number: 1354 • ACR Convergence 2023
The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus
Ceshae Harding¹, Amanda Eudy², Catherine Sims¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Mental health conditions are the leading cause of maternal mortality across most of the United States. Among individuals with SLE, pregnancy intention has been…
Abstract Number: 1993 • ACR Convergence 2023
Impact of Metabolic Syndrome on Ultrasonographic Findings and Quality of Life in Patients with Early Osteoarthritis
Maria Fernanda Gonzalez-Hernandez¹, Rolando Espinosa-Morales², Carlos Pineda², Angelica Peña³, Araceli Bernal¹ and Alejandra Alabarda¹, ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ³Instituto Mexicano del Seguro Social, Querétaro, Mexico
Background/Purpose: Osteoarthritis (OA) is a common disorder with increased incidence with age. Metabolic syndrome (MS) is frequently associated with OA, although other factors are considered…
Abstract Number: 2471 • ACR Convergence 2023
Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts
Sabryne Berkani¹, Ainhoa Aparicio Monforte², Sophie tuffet², alexandra rousseau², nathalie rincheval³, emmanuel maheu⁴, bernard combe³, Alain SARAUX⁵, Bruno Fautrel⁶, Laure Gossec⁷, Francis Berenbaum⁴, Jeremie SELLAM⁶ and alice courties⁴, ¹Sorbonne Université, Rheumatology department, (AP-HP) Saint-Antoine Hospital, Paris, France, ²Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), APHP, Hôpital St Antoine, Paris, France, ³Department of Rheumatology, University of Montpellier, Montpellier, France, ⁴Sorbonne Université Assistance Publique – Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Department of Rheumatology, Paris, France, ⁵CHU Brest, Brest, France, ⁶Sorbonne Université APHP, Paris, France, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Hand osteoarthritis (HOA) is considered as a less severe disease with a better functional prognosis and a lower global burden than rheumatoid arthritis (RA).…
Abstract Number: 0337 • ACR Convergence 2023
Impact of Photosensitivity on Quality of Life in Dermatomyositis
Kirubel Gebre¹, Rachita Pandya², Julianne Kleitsch², Darosa Lim³, Rui Feng³ and victoria werth⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Lancaster, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Wynnewood, PA
Background/Purpose: Photosensitivity (PS) has been documented in dermatomyositis (DM) with symptoms including aggravation of preexisting cutaneous lesions and abnormal transient erythemal responses (Cheong WK et…
Abstract Number: 0819 • ACR Convergence 2023
Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Improvement in pain reported in clinical trials for osteoarthritis (OA) is typically strongly depending on the regression-to-the-mean phenomenon. Regression to the mean has been…
Abstract Number: 1368 • ACR Convergence 2023
Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s
Benjamin A Fisher¹, Linda Stone², Jessica Marvel³, Pushpendra Goswami⁴, Monia Steenackers⁴, Gayle Kenney⁴, Chiara Perella⁵, Wolfgang Hueber⁴, Chloe Howse⁶, Elizabeth Gargon⁶, Aishwarya Chohan⁶, Megan Mayhew⁶ and Nicola Williamson⁶, ¹University of Birmingham, Birmingham, United Kingdom, ²The British Sjogren’s Syndrome Association, Birmingham, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Riehen, Switzerland, ⁶Adelphi Values Patient-Centered Outcomes, Bollington, United Kingdom
Background/Purpose: Sjögren's is a heterogenous chronic auto-immune disease, characterized by excessive dryness of the eyes and mouth, as well as systemic complications which can significantly…
Abstract Number: 2022 • ACR Convergence 2023
Development of an mHealth App for Lupus: Insights from a Human-Centered Design Approach
Anna Deck¹, Kiran Singh², Lucas Dantas³, Amy LeClair², Lisa Mandl⁴, Timothy McAlindon⁵, Faye Chiu⁶, Monique Gore-Massy⁷ and Shanthini Kasturi², ¹Tufts University School of Medicine, Boston, MA, ²Tufts Medical Center, Boston, MA, ³Ambulomics, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Tufts Medical Center, Arlington, MA, ⁶N/A, New York, NY, ⁷Covid-19 GRA, West Orange, NJ
Background/Purpose: Mobile health (mHealth) technology offers promising tools to facilitate the self-management of chronic diseases, including systemic lupus erythematosus (SLE). However, currently available mHealth applications…
Abstract Number: 2556 • ACR Convergence 2023
End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort
Jiacai Cho¹, Liang Shen², Rangi Kandane-Rathnayake³, Vera Golder³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yeong-Jian J Wu⁸, Leonid Zamora⁹, Zhanguo Li¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhuoli Zhang¹⁴, BMDB Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Shereen Oon²⁰, Sean O’Neill²¹, Fiona Goldblatt²², Kristine Ng²³, Annie Law²⁴, Nicola Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra⁹, Chak Sing Lau²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹, Eric Morand³² and Aisha Lateef³³, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Peking University People’s Hospital, Beijing, China, ¹¹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ¹⁶Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁷Keio University, Keio, Japan, ¹⁸Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²⁰Department of Medicine, The University of Melbourne at St Vincent’s Hospital, Melbourne, Australia, ²¹Department of Medicine, University of New South Wales, Kensington, Australia, ²²Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²³Waitemata DHB, Auckland, New Zealand, ²⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²⁵Auckland District Health Board, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Manila, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ³²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³³National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore
Background/Purpose: SLE patients suffer high symptom burden at the end-of-life. However, the course of disease and treatment burden in the last year of life have…
Abstract Number: 026 • 2023 Pediatric Rheumatology Symposium
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Sophie Stefancic, Amanda Robinson, Haley Havrilla, Samantha Branton, Vibha Sood and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gastrointestinal (GI) manifestations in juvenile onset systemic sclerosis (jSSc) reflect adult disease with a range of involvement along the GI tract, including oropharyngeal dysphagia…
Abstract Number: 030 • 2023 Pediatric Rheumatology Symposium
International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update
Christina ZIgler¹, Debra Henke², Clare Pain³, Hanna Lythgoe³, Kaveh Ardalan², Kathryn Torok⁴ and Suzanne Li⁵, ¹Duke, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare condition causing inflammation and fibrosis that may impair health-related quality of life (HRQoL). Recent studies demonstrate extracutaneous…
Abstract Number: 042 • 2023 Pediatric Rheumatology Symposium
Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Sara Patrizi¹, Susmita Kashikar-Zuck², CARRA Registry Investigators³, Mekibib Altaye⁴ and Jennifer Weiss⁵, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³CARRA, Washington, DC, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, Hackensack, NJ
Background/Purpose: The prevalence, severity and impact of chronic pain in pediatric patients with autoimmune diseases such as childhood onset SLE (cSLE) and juvenile dermatomyositis (JDM)…
Abstract Number: 052 • 2023 Pediatric Rheumatology Symposium
Extreme Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA): A Discrete Group of Patients
Yoel Levinsky¹, Rotem Tal², Liora Harel², Shoval Shoham³, Sabreen Abu Ahmad⁴, Yonatan Butbul Aviel⁵, Gil Amarilyo² and Mor Broide³, ¹Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ²Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Ruth Rappaport Children's Hospital, Rambam Health Care, Haifa, Israel, ⁵Rambam Medical center, Haifa, Israel
Background/Purpose: Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children; by definition, episodes occur every…
Abstract Number: 0444 • ACR Convergence 2022
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Cristina Burroughs³, Kalen Larson², Christine Yeung⁴, Peter Merkel⁵ and Robert Spiera⁶, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in…
Abstract Number: 1495 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in…

« Previous Page
1
…
8
9
10
11
12
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.